NCT03226418View on ClinicalTrials.gov

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 7, 2017

Primary Completion Date

March 16, 2024

Study Completion Date

October 1, 2024

Conditions

Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid Leukemia

Interventions

DRUG

Cytarabine

Given IV

DRUG

Decitabine

Given IV

DRUG

Idarubicin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Azacitidine

Given by infusion

DRUG

Venetoclax

oral tablet

DRUG

glasdegib

oral tablet

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Nebraska

OTHER

NCT03226418 - Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter